SMN2 and proximal spinal muscular atrophy: For the first time, glutamate toxicity mediated by the downregulation of EAAT1 has been identified as a significant driving force for early MN loss in late-onset SMA, and qualifies EAAT1 as a potential therapeutic target for SMN-independent treatment strategies to complement SMN-enhancing drugs in late-onset SMA therapy.